GL
Monte Rosa Therapeutics, Inc.
GLUE · NASDAQ
$12.99 -6.14% (-$0.85)
1M -8.52%
Market Cap $1.17B
P/E Ratio -
Div. Yield -
ROE 43.31%
Bulios Fair Price
$7.97
38.6% downside
Trenutna cena
$12.99
Podcenjeno Poštena vrednost Precenjeno
Po podatkih Bulios Fair Price je delnica GLUE trenutno precenjena glede na svojo tržno ceno. Kako deluje?
Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?
Piotroski F-Score Weak
2/9Valuation
39 /100
Fair P/B 2.41x
P/S 40.88x
EV/FFO N/A
Growth
0 /100
Declining Book val. growth 4.95%
FCF growth N/A
EPS growth N/A
Profitability
20 /100
Weak Op. margin 633.04%
Gross margin 92.94%
FCF margin 248.25%
Quality
0 /100
Poor ROA 23.15%
ROIC 28.09%
Asset turnover 0.04x
Debt
100 /100
Low Current ratio 9.52x
Debt/Equity 0.08x
Debt/Assets N/A
Stability
33 /100
Unstable Profitable years 0
Beta 1.50x
EPS volatility 41.99%
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o GLUE
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Markus Warmuth
Employees
173
Headquarters
Boston
Prihajajoči dogodki
05 NOV.
Earnings
Upcoming earnings report